Glenmark Pharmaceuticals Opens Monoclonal Antibody Manufacturing Facility - - BioPharm International

ADVERTISEMENT

Glenmark Pharmaceuticals Opens Monoclonal Antibody Manufacturing Facility


Glenmark Pharmaceuticals, India, has opened a new cGMP-compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. This manufacturing facility supplements Glenmark's existing in-house discovery and development capabilities and will supply material for clinical development.

Glenmark Pharmaceuticals' Swiss research center has in-house capabilities and infrastructure for conducting antibody discovery, cell-line development, in-vitro testing and characterization of antibodies, process development, and analytical research. The new manufacturing facility supplements the research and development capabilities and will facilitate production of clinical grade material. The manufacturing facility has been designed for use of single-use bioreactor systems and also houses a suite for manufacturing cell banks.

Source: Glenmark Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
Author Guidelines

Click here